Baillie Gifford acquired 15.7 Million Dexcom shares worth $2.01 Billion. That's 1.57% of their equity portfolio (17th largest holding). The investor owns 3.94% of the outstanding Dexcom stock. The first Dexcom trade was made in Q1 2013. Since then Baillie Gifford bought shares fifteen more times and sold shares on 28 occasions. The stake costed the investor $538 Million, netting the investor a gain of 274% so far.